Literature DB >> 2786405

Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up.

O Lindvall1, S Rehncrona, P Brundin, B Gustavii, B Astedt, H Widner, T Lindholm, A Björklund, K L Leenders, J C Rothwell, R Frackowiak, D Marsden, B Johnels, G Steg, R Freedman, B J Hoffer, A Seiger, M Bygdeman, I Strömberg, L Olson.   

Abstract

By using stereotaxic surgical techniques, ventral mesencephalic tissues from aborted human fetuses of 8 to 10 weeks' gestational age were implanted unilaterally into the striata in two patients with advanced Parkinson's disease. The patients were treated with a cyclosporine, azathioprine, and steroid regimen to minimize the risk for graft rejection. They were examined for 6 months preoperatively and 6 months postoperatively and continued to receive the same doses of antiparkinsonian medication. There were no significant postoperative complications. No major therapeutic effect from the operation was observed. However, in the clinical tests, both patients showed small but significant increases of movement speed for repeated pronation-supination, fist clenching, and foot lifting. The rate of walking also increased in the one patient tested. For both patients, there was an initial worsening postoperatively, followed by improvement vs preoperative performance at 1 to 3 months. Both patients also showed significant improvement in the magnitude of response to a single dose of levodopa (L-dopa), but there was no increase in the duration of drug action. The motor readiness potential increased in both patients postoperatively, primarily over the operated hemisphere. Neurophysiological measurements also showed a more rapid performance of simple and complex arm and hand movements on the side contralateral to transplantation in one patient at 5 months postoperatively. Positron emission tomography demonstrated no increased uptake of 6-L-(18F)-fluorodopa in the transplanted striatum at 5 and 6 months. Taken together, these results suggest that the fetal nigral implants may have provided a modest improvement in motor function, consistent with the presence of small surviving grafts. Although our results support further scientific experimentation with transplantation in Parkinson's disease, widespread clinical trials with this procedure are probably not warranted at this time.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2786405     DOI: 10.1001/archneur.1989.00520420033021

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  59 in total

Review 1.  Gene transfer approaches to the lysosomal storage disorders.

Authors:  J A Barranger; E O Rice; W P Swaney
Journal:  Neurochem Res       Date:  1999-04       Impact factor: 3.996

2.  Cryopreservation, survival and function of intrastriatal fetal mesencephalic grafts in a rat model of Parkinson's disease.

Authors:  H Sauer; E M Frodl; A Kupsch; G ten Bruggencate; W H Oertel
Journal:  Exp Brain Res       Date:  1992       Impact factor: 1.972

Review 3.  Cell implantation in Parkinson's disease.

Authors:  A Williams
Journal:  BMJ       Date:  1990-08-11

4.  Implanting fetal tissue to treat Parkinson's disease.

Authors:  R E Breeze
Journal:  West J Med       Date:  1990-11

Review 5.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

6.  Large animal models are critical for rationally advancing regenerative therapies.

Authors:  Dustin R Wakeman; Andrew M Crain; Evan Y Snyder
Journal:  Regen Med       Date:  2006-07       Impact factor: 3.806

7.  Neuropharmacology of dopamine receptors:: Implications in neuropsychiatric diseases.

Authors:  F I Tarazi
Journal:  J Sci Res Med Sci       Date:  2001-10

8.  Motor function, graft survival and gliosis in rats with 6-OHDA lesions and foetal ventral mesencephalic grafts chronically treated with L-dopa and carbidopa.

Authors:  S B Blunt; P Jenner; C D Marsden
Journal:  Exp Brain Res       Date:  1992       Impact factor: 1.972

Review 9.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

Review 10.  Mesenchymal stem cells secretome: a new paradigm for central nervous system regeneration?

Authors:  Fábio G Teixeira; Miguel M Carvalho; Nuno Sousa; António J Salgado
Journal:  Cell Mol Life Sci       Date:  2013-03-01       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.